← All trials
NCT06945107
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 27, 2025
- Primary completion
- Jun 7, 2026
- Completion date
- Jan 19, 2027
- First posted
- Apr 25, 2025
- Last posted
- Jun 12, 2025
- Enrollment
- 310
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Innovent Biologics (Suzhou) Co. Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.